Antimicrobial susceptibility of <i>Stenotrophomonas maltophilia</i> from United States medical centers (2019–2023)
Hélio S. Sader, Mariana Castanheira, S J Ryan Arends, Timothy B Doyle
Abstract
ABSTRACT We evaluated the antimicrobial susceptibility of 1,400 clinical isolates of Stenotrophomonas maltophilia consecutively collected from United States medical centers in 2019–2023. Aztreonam-avibactam (MIC 50/90 , 2/4 µg/mL; 99.6% inhibited at ≤8 µg/mL) was the most active compound, followed by trimethoprim-sulfamethoxazole (MIC 50/90 , ≤0.12/0.5 µg/mL; 96.9% susceptible), minocycline (MIC 50/90 , 0.5/2 µg/mL; 89.2% susceptible), and levofloxacin (MIC 50/90 , 1/8 µg/mL; 78.9% susceptible). Aztreonam-avibactam retained potent activity against isolates not susceptible to trimethoprim-sulfamethoxazole, minocycline, and/or levofloxacin (99.3%–100.0% inhibited at ≤8 µg/mL).